C.Q. Pharmaceutical Holding Co., Ltd.

SZSE:000950 Stock Report

Market Cap: CN¥9.9b

C.Q. Pharmaceutical Holding Valuation

Is 000950 undervalued compared to its fair value, analyst forecasts and its price relative to the market?

Valuation Score

2/6

Valuation Score 2/6

  • Below Fair Value

  • Significantly Below Fair Value

  • Price-To-Earnings vs Peers

  • Price-To-Earnings vs Industry

  • Price-To-Earnings vs Fair Ratio

  • Analyst Forecast

Share Price vs Fair Value

What is the Fair Price of 000950 when looking at its future cash flows? For this estimate we use a Discounted Cash Flow model.

Below Fair Value: 000950 (CN¥5.53) is trading above our estimate of fair value (CN¥0.7)

Significantly Below Fair Value: 000950 is trading above our estimate of fair value.

Key Valuation Metric

Which metric is best to use when looking at relative valuation for 000950?

Key metric: As 000950 is profitable we use its Price-To-Earnings Ratio for relative valuation analysis.

The above table shows the Price to Earnings ratio for 000950. This is calculated by dividing 000950's market cap by their current earnings.
What is 000950's PE Ratio?
PE Ratio22.2x
EarningsCN¥429.57m
Market CapCN¥9.94b

Price to Earnings Ratio vs Peers

How does 000950's PE Ratio compare to its peers?

The above table shows the PE ratio for 000950 vs its peers. Here we also display the market cap and forecasted growth for additional consideration.
CompanyForward PEEstimated GrowthMarket Cap
Peer Average17.2x
603368 Guangxi LiuYao Group
8.2x16.0%CN¥7.6b
600211 Tibet Rhodiola Pharmaceutical Holding
15.9x25.7%CN¥12.3b
600713 NanJing Pharmaceutical
12xn/aCN¥7.2b
301370 GKHT Medical Technology
32.8xn/aCN¥5.6b
000950 C.Q. Pharmaceutical Holding
22.2x29.7%CN¥9.9b

Price-To-Earnings vs Peers: 000950 is expensive based on its Price-To-Earnings Ratio (22.2x) compared to the peer average (17.2x).

Price to Earnings Ratio vs Industry

How does 000950's PE Ratio compare vs other companies in the CN Healthcare Industry?

0 CompaniesPrice / EarningsEstimated GrowthMarket Cap
No more companies available in this PE range
000950 22.2xIndustry Avg. 34.5xNo. of Companies7PE020406080100+
0 CompaniesEstimated GrowthMarket Cap
No more companies

Price-To-Earnings vs Industry: 000950 is good value based on its Price-To-Earnings Ratio (22.2x) compared to the CN Healthcare industry average (34.5x).

Price to Earnings Ratio vs Fair Ratio

What is 000950's PE Ratio compared to its Fair PE Ratio? This is the expected PE Ratio taking into account the company's forecast earnings growth, profit margins and other risk factors.

000950 PE Ratio vs Fair Ratio.
Fair Ratio
Current PE Ratio22.2x
Fair PE Ratio27.8x

Price-To-Earnings vs Fair Ratio: 000950 is good value based on its Price-To-Earnings Ratio (22.2x) compared to the estimated Fair Price-To-Earnings Ratio (27.8x).

Analyst Price Targets

What is the analyst 12-month forecast and do we have any statistical confidence in the consensus price target?

Analyst Forecast: Insufficient data to show price forecast.

Discover undervalued companies

Shenzhen Lifotronic Technology

CN¥7.1b

Research, develops, manufactures, and markets medical devices for diagnostics, clinical medicine, skin, and human health related purposes in China.

688389

CN¥15.53

7D

-5.8%

1Y

-34.9%

Innovita Biological Technology

CN¥6.0b

Engages in the research and development, manufacturing, marketing, and sales of POCT rapid diagnostic products.

688253

CN¥44.03

7D

2.4%

1Y

46.3%

iRay Technology

CN¥16.1b

Develops, manufactures, and sells flat panel X-ray detectors for use in medical, dental, oncology, veterinary, security, and industrial imaging applications in China and internationally.

688301

CN¥108.85

7D

-3.0%

1Y

-32.1%